Welcome to our dedicated page for AI Maverick news (Ticker: AIMV), a resource for investors and traders seeking the latest updates and insights on AI Maverick stock.
AI Maverick Intel, Inc. (AIMV) is a technology-driven company centered on artificial intelligence for business growth, and its news flow reflects that focus. The company highlights its AI Maverick platform as a tool for helping partners acquire and engage customers, close deals, and scale revenue, and corporate announcements often relate to this AI-enabled mission.
News about AIMV can include updates on its corporate identity and trading symbol, such as the change to AIMV on the OTC Market that the company described as a milestone in its transition to AI Maverick Intel. Coverage may also feature communications about its strategic direction, including references to joint venture initiatives designed to leverage its AI Maverick technology for customer acquisition and partner commercialization.
Investors and observers following AIMV’s news can look for company statements on how it positions itself as an AI-powered platform company, along with developments connected to its rebranding from Bionoid Pharma, Inc. to AI Maverick Intel, Inc. These items provide context on how the company presents its role in applying artificial intelligence to business development and revenue-focused activities.
This news page aggregates such company-related updates in one place, making it easier to review AIMV’s public announcements about its AI focus, symbol changes, and partnership-oriented growth plans over time.
AI Maverick Intel (AIMV) entered a non-binding LOI to acquire 100% of HEAL Access Canada (HAC) as the first transaction under a ROFR framework with HEAL.
Consideration would include 20,000,000 exchangeable AIMV shares and a secured vendor take-back note of ~USD$5.0 million; closing requires AIMV to have at least USD$5.0 million net positive working capital. Definitive agreement is targeted by May 29, 2026.
AI Maverick Intel (NASDAQ: AIMV) entered a Right of First Refusal agreement with HEAL Group Holdings effective February 11, 2026, giving AIMV the option to match third-party offers for certain HEAL assets during a defined exercise period.
AIMV will issue 120,000,000 common shares at a deemed price of US$0.02 per share (aggregate US$2.4 million) as consideration. The ROFR covers HEAL's AI-driven healthcare technology, services, and distribution businesses across more than six countries and remains in effect for three years unless mutually terminated.
AI Maverick Intel (OTC:AIMV) announced that effective Oct. 20, 2025 its common shares will trade under the new ticker AIMV following the company's rebranding from Bionoid Pharma to AI Maverick Intel.
The change aligns the market identity with the company's strategic focus on AI-driven customer acquisition, partner-led deal flow, and revenue acceleration via its AI Maverick platform. The company said its CUSIP and corporate structure remain unchanged and shareholders are not required to take any action. Management expects to finalize strategic JV initiatives in Q4 2025 to broaden commercialization and accelerate customer acquisition.